{"id":"open-label-denosumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypocalcemia"},{"rate":null,"effect":"Osteonecrosis of the jaw"},{"rate":null,"effect":"Atypical femoral fractures"},{"rate":null,"effect":"Infections"},{"rate":null,"effect":"Back pain"}]},"_chembl":{"chemblId":"CHEMBL1237023","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Denosumab binds to RANKL, a key mediator of osteoclast differentiation and activation. By preventing RANKL from engaging its receptor RANK on osteoclast precursors, the drug suppresses bone resorption and increases bone mineral density. This mechanism makes it effective for conditions characterized by excessive bone loss or osteolytic lesions.","oneSentence":"Denosumab is a monoclonal antibody that inhibits RANKL (receptor activator of nuclear factor kappa-B ligand), blocking osteoclast formation and bone resorption.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:24:25.892Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of skeletal-related events in patients with bone metastases from solid tumors"},{"name":"Treatment of osteoporosis in postmenopausal women"},{"name":"Giant cell tumor of bone"}]},"trialDetails":[{"nctId":"NCT06588153","phase":"PHASE4","title":"A Study for the Evaluation of Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland China","status":"RECRUITING","sponsor":"Amgen","startDate":"2025-05-24","conditions":"Glucocorticoid-induced Osteoporosis","enrollment":100},{"nctId":"NCT06332014","phase":"PHASE4","title":"Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2024-08-06","conditions":"Osteoporosis","enrollment":102},{"nctId":"NCT04586660","phase":"PHASE4","title":"Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2023-08-17","conditions":"Giant Cell Tumor of Bone","enrollment":36},{"nctId":"NCT05630768","phase":"PHASE4","title":"Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2023-01-03","conditions":"Postmenopausal Osteoporosis","enrollment":149},{"nctId":"NCT04907539","phase":"PHASE2","title":"A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)","status":"COMPLETED","sponsor":"Redx Pharma Ltd","startDate":"2021-11-08","conditions":"Colorectal Cancer","enrollment":25},{"nctId":"NCT04907851","phase":"PHASE2","title":"A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2)","status":"COMPLETED","sponsor":"Redx Pharma Ltd","startDate":"2021-12-10","conditions":"Advanced Solid Tumours","enrollment":45},{"nctId":"NCT05361408","phase":"PHASE4","title":"A Clinical Trial to Evaluate Efficacy of Once or Twice ZOledronic Acid After Different Duration of denOsumMab Administration in Postmenopausal Women With Osteoporosis (ZOOM Study)","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2022-02-11","conditions":"Osteoporosis","enrollment":114},{"nctId":"NCT05966064","phase":"PHASE4","title":"DEnosumab for the Treatment of FIbrous Dysplasia/McCune-Albright Syndrome in Adults (DeFiD)","status":"RECRUITING","sponsor":"Natasha Appelman-Dijkstra","startDate":"2023-06-13","conditions":"Fibrous Dysplasia, McCune Albright Syndrome","enrollment":82},{"nctId":"NCT03270020","phase":"PHASE2","title":"Denosumab for the Treatment of Adult LCH","status":"COMPLETED","sponsor":"Hellenic Society for the Study of Bone Metabolism","startDate":"2017-09-07","conditions":"Langerhans Cell Histiocytosis","enrollment":10},{"nctId":"NCT02771860","phase":"PHASE2","title":"RANKL-blockade for the Treatment of Erosive Osteoarthritis (OA) of Interphalangeal Finger Joints","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2016-03","conditions":"Hand Osteoarthritis","enrollment":100},{"nctId":"NCT02129699","phase":"PHASE3","title":"Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy","status":"TERMINATED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2015-01-06","conditions":"Lung Cancer Non-small Cell Stage IV","enrollment":595},{"nctId":"NCT03925532","phase":"PHASE2","title":"Denosumab in Treating Patients With Bone Loss Due to Donor Stem Cell Transplant","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2019-12-19","conditions":"Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Osteopenia, Osteoporosis","enrollment":30},{"nctId":"NCT00556374","phase":"PHASE3","title":"Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-12-18","conditions":"Breast Cancer","enrollment":3420},{"nctId":"NCT03638128","phase":"PHASE3","title":"Open-label Extension of Study 20130173 of Denosumab in Children and Young Adults With Osteogenesis Imperfecta","status":"TERMINATED","sponsor":"Amgen","startDate":"2018-07-26","conditions":"Osteogenesis Imperfecta (OI)","enrollment":75},{"nctId":"NCT00396279","phase":"PHASE2","title":"Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-07-10","conditions":"GCT, Giant Cell Tumor of Bone","enrollment":37},{"nctId":"NCT01345019","phase":"PHASE3","title":"Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-05-17","conditions":"Cancer, Hematologic Malignancies, Multiple Myeloma","enrollment":1718},{"nctId":"NCT00523341","phase":"PHASE3","title":"Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis","status":"COMPLETED","sponsor":"Amgen","startDate":"2007-08-07","conditions":"Osteopenia, Osteoporosis","enrollment":4550},{"nctId":"NCT00680992","phase":"PHASE2","title":"Study of Denosumab in Subjects With Giant Cell Tumor of Bone","status":"COMPLETED","sponsor":"Amgen","startDate":"2008-09-09","conditions":"Cancer, Giant Cell Tumors, Giant Cell Tumor of Bone","enrollment":535},{"nctId":"NCT00896532","phase":"PHASE2","title":"Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-06-03","conditions":"Low Bone Mineral Density, Postmenopausal Osteoporosis","enrollment":419},{"nctId":"NCT03571191","phase":"PHASE2","title":"Denosumab Treatment for Fibrous Dysplasia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Dental and Craniofacial Research (NIDCR)","startDate":"2019-06-13","conditions":"Bone Diseases, Pain","enrollment":9},{"nctId":"NCT03691311","phase":"EARLY_PHASE1","title":"Biomarker Study of the Antitumoral Activity of Denosumab in the Pre- Operative Setting of Early Breast Cancer","status":"UNKNOWN","sponsor":"Institut Català d'Oncologia","startDate":"2018-07-05","conditions":"Breast Neoplasm Female, Stage I Breast Cancer, Stage II Breast Cancer","enrollment":60},{"nctId":"NCT00919711","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Denosumab and Actonel® in Post Menopausal Women Transitioned From Alendronate Therapy","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-09-01","conditions":"Osteoporosis","enrollment":870},{"nctId":"NCT00518531","phase":"PHASE3","title":"Denosumab Adherence Preference Satisfaction Study","status":"COMPLETED","sponsor":"Amgen","startDate":"2007-09-01","conditions":"Osteoporosis","enrollment":250},{"nctId":"NCT01419717","phase":"PHASE3","title":"Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2011-11-22","conditions":"Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer","enrollment":129},{"nctId":"NCT03605199","phase":"PHASE2","title":"Denosumab in Subjects With Giant Cell Rich Tumors of Bone","status":"UNKNOWN","sponsor":"Leiden University Medical Center","startDate":"2018-06-18","conditions":"Aneurysmal Bone Cysts, Giant Cell Granuloma, Osteoblastoma","enrollment":60},{"nctId":"NCT03070002","phase":"PHASE2","title":"Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2017-10-19","conditions":"Breast Carcinoma Metastatic in the Bone, Circulating Tumor Cell Count, Estrogen Receptor Positive","enrollment":1},{"nctId":"NCT00838201","phase":"PHASE3","title":"Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-02-01","conditions":"Cancer, Carcinoma, Castrate-Resistant Prostate Cancer","enrollment":384},{"nctId":"NCT00286091","phase":"PHASE3","title":"Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-01-24","conditions":"Hormone Refractory Prostate Cancer","enrollment":1435},{"nctId":"NCT00980174","phase":"PHASE3","title":"Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-10-01","conditions":"Low Bone Mass, Low Bone Mineral Density, Males With Osteoporosis","enrollment":242},{"nctId":"NCT02321280","phase":"PHASE1, PHASE2","title":"The Efficacy of Denosumab in Active Crohn's Disease","status":"COMPLETED","sponsor":"University of Manitoba","startDate":"2015-02","conditions":"Crohn Disease","enrollment":2},{"nctId":"NCT00325468","phase":"PHASE3","title":"An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration in Postmenopausal Women With Low Bone Mineral Density","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-05-01","conditions":"Low Bone Mineral Density","enrollment":200},{"nctId":"NCT00259740","phase":"PHASE2","title":"Open-Label, Phase 2, Proof of Concept Study in Multiple Myeloma - Denosumab","status":"COMPLETED","sponsor":"Amgen","startDate":"2005-11","conditions":"Relapsed or Plateau-Phase Multiple Myeloma","enrollment":96},{"nctId":"NCT01377467","phase":"PHASE3","title":"Denosumab for Prevention of Osteoporosis in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Rudolf Wuethrich","startDate":"2011-06","conditions":"Osteoporosis, Chronic Kidney Disease","enrollment":90},{"nctId":"NCT01464931","phase":"PHASE1","title":"Multiple Dose Study to Evaluate the Safety of Multiple Doses of Denosumab 120 mg in Adults With Severe Chronic Kidney Disease (CKD) and CKD on Dialysis","status":"COMPLETED","sponsor":"Amgen","startDate":"2011-11","conditions":"Renal Impairment","enrollment":32},{"nctId":"NCT02099461","phase":"PHASE1","title":"Effect of Denosumab on Cellular Biomarkers in the Human Breast","status":"COMPLETED","sponsor":"Amgen","startDate":"2014-04","conditions":"Healthy Volunteer, Female, Breast","enrollment":82},{"nctId":"NCT00680953","phase":"PHASE3","title":"Denosumab Fracture Intervention Randomized Placebo Controlled Trial in Japanese Patients With Osteoporosis","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2008-05","conditions":"Osteoporosis","enrollment":1262},{"nctId":"NCT01824342","phase":"PHASE3","title":"Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2011-01","conditions":"Castrate-resistant Prostate Cancer","enrollment":18},{"nctId":"NCT02101164","phase":"PHASE4","title":"Evaluate Time Associated With the Preparation & Administration of Denosumab/Pamidronate in Patients With Solid Tumors and Metastatic Bone Disease","status":"WITHDRAWN","sponsor":"Amgen","startDate":"2014-11","conditions":"Solid Tumor, Metastatic Bone Disease","enrollment":""},{"nctId":"NCT01869686","phase":"PHASE1","title":"Study to Evaluate the Concentration of Denosumab in Seminal Fluid in Healthy Men After a Single Subcutaneous Dose","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-06","conditions":"Healthy Volunteer","enrollment":12},{"nctId":"NCT01457950","phase":"PHASE3","title":"A Study in Korean Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-11","conditions":"Osteoporosis, Postmenopausal","enrollment":135},{"nctId":"NCT00950911","phase":"PHASE3","title":"Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-07","conditions":"Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer, Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma","enrollment":35},{"nctId":"NCT00091832","phase":"PHASE2","title":"Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2004-09","conditions":"Breast Cancer, Metastases, Bone Metastases in Subjects With Advanced Breast Cancer","enrollment":255},{"nctId":"NCT00515463","phase":"PHASE3","title":"A Multi-Center, Randomized, Open-Label Study to Assess the Immunogenicity and Safety of Denosumab in Pre-filled Syringe Compared to Vial in Subjects With Low Bone Mineral Density","status":"COMPLETED","sponsor":"Amgen","startDate":"2007-05","conditions":"Low Bone Mineral Density, Osteopenia, Osteoporosis","enrollment":311},{"nctId":"NCT00043186","phase":"PHASE2","title":"Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density","status":"COMPLETED","sponsor":"Amgen","startDate":"2002-05","conditions":"Low Bone Mineral Density","enrollment":412},{"nctId":"NCT00936897","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-07","conditions":"Postmenopausal Osteoporosis","enrollment":833},{"nctId":"NCT00104650","phase":"PHASE2","title":"Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates","status":"COMPLETED","sponsor":"Amgen","startDate":"2005-01","conditions":"Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer, Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma","enrollment":111}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"open-label denosumab","genericName":"open-label denosumab","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Denosumab is an open-label study intervention that targets tumor necrosis factor ligand superfamily member 11, an inhibitor of this protein. It is used to treat conditions such as osteoporosis, colorectal cancer, low bone mass, and low bone mineral density, and is administered subcutaneously.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}